Back

Semaglutide is associated with lower rates of cardiovascular outcomes and death than positive airway pressure in patients with overweight/obesity and sleep apnea: a propensity score matching study.

30 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Adiposity and the heart (3) Obesity ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Luciano Drager

University of Sao Paulo, Sao Paulo (Brazil)

5 More presentations in this session

Presentation thumbnail
Epicardial adipose tissue in children with obesity: correlations with cardiometabolic parameters and treatment response
Mrs S. Bidstrup Groth (DK)
Abstract Slides
Presentation thumbnail
Adipose tissue distribution, cognitive decline and structural brain changes in individuals with cardiovascular disease: the SMART-MR study
Ms R. Bhattacharya (Utrecht, NL)
Abstract Slides
Presentation thumbnail
The role of 3D body scan derived anthropometric measurements in predicting subclinical atherosclerosis in the REACT cohort
Ms A. Dufva (DK)
Abstract Slides
Presentation thumbnail
Apolipoprotein b level elevation and glutathionylated proteins as new biomarkers for cardiac hypertrophy in children
Doctor M. Silvetti (Rome, IT)
Abstract Slides
Presentation thumbnail
Obesity-associated mortality in myocardial disease: a nationwide trend analysis using CDC WONDER (1999–2020)
Doctor S. Waqas (Royal Oak, US)
Abstract Slides

Access the full session

Session thumbnail
Adiposity and the heart (3)

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnoea: A real-world propensity score-matched study
30 August 2025
thumbnail
Congress Presentation
Bariatric surgery is associated with lower risk of acute cardiovascular events in patients with obesity and hypertrophic cardiomyopathy
27 August 2021
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Impact of obstructive sleep apnea in patients undergoing left ventricular assist device implantation
23 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources